Literature DB >> 33162397

Local steroid activation is a critical mediator of the anti-inflammatory actions of therapeutic glucocorticoids.

Chloe Fenton1,2, Claire Martin1, Rachel Jones1,3, Adam Croft2, Joana Campos2, Amy J Naylor2,4, Angela E Taylor1,5, Myriam Chimen2,6, Mark Cooper7, Gareth G Lavery1,3,5, Karim Raza2,8, Rowan S Hardy9,3,6.   

Abstract

OBJECTIVES: The enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) plays a well-characterised role in the metabolism and activation of endogenous glucocorticoids (GCs). However, despite its potent upregulation at sites of inflammation, its role in peripheral metabolism and action of therapeutic GCs remains poorly understood. We investigated the contribution of 11β-HSD1 to the anti-inflammatory properties of the active GC corticosterone, administered at therapeutic doses in murine models of polyarthritis.
METHODS: Using the tumour necrosis factor-tg and K/BxN serum-induced models of polyarthritis, we examined the anti-inflammatory properties of oral administration of corticosterone in animals with global, myeloid and mesenchymal targeted transgenic deletion of 11β-HSD1. Disease activity and joint inflammation were scored daily. Joint destruction and measures of local and systemic inflammation were determined by histology, micro-CT, quantitative RT-PCR, fluorescence activated cell sorting and ELISA.
RESULTS: Global deletion of 11β-HSD1 resulted in a profound GC resistance in animals receiving corticosterone, characterised by persistent synovitis, joint destruction and inflammatory leucocyte infiltration. This was partially reproduced with myeloid, but not mesenchymal 11β-HSD1 deletion, where paracrine GC signalling between cell populations was shown to overcome targeted deletion of 11β-HSD1.
CONCLUSIONS: We identify an entirely novel component of therapeutic GC action, whereby following their systemic metabolism, they require peripheral reactivation and amplification by 11β-HSD1 at sites of inflammation to deliver their anti-inflammatory therapeutic effects. This study provides a novel mechanistic understanding of the anti-inflammatory properties of therapeutic GCs and their targeting to sites of inflammation in polyarthritis. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

Entities:  

Keywords:  arthritis; experimental; glucocorticoids; inflammation; synovitis

Mesh:

Substances:

Year:  2020        PMID: 33162397      PMCID: PMC7815637          DOI: 10.1136/annrheumdis-2020-218493

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  31 in total

1.  The anti-inflammatory effect of glucocorticoids is mediated by glucocorticoid-induced leucine zipper in epithelial cells.

Authors:  Jane Eddleston; Jack Herschbach; Amy L Wagelie-Steffen; Sandra C Christiansen; Bruce L Zuraw
Journal:  J Allergy Clin Immunol       Date:  2006-10-13       Impact factor: 10.793

2.  Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma.

Authors:  J F Dunn; B C Nisula; D Rodbard
Journal:  J Clin Endocrinol Metab       Date:  1981-07       Impact factor: 5.958

3.  Conditional inactivation of FGF receptor 2 reveals an essential role for FGF signaling in the regulation of osteoblast function and bone growth.

Authors:  Kai Yu; Jingsong Xu; Zhonghao Liu; Drazen Sosic; Jiansu Shao; Eric N Olson; Dwight A Towler; David M Ornitz
Journal:  Development       Date:  2003-07       Impact factor: 6.868

4.  Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy.

Authors:  Jan P Tuckermann; Anna Kleiman; Richard Moriggl; Rainer Spanbroek; Anita Neumann; Anett Illing; Björn E Clausen; Brenda Stride; Irmgard Förster; Andreas J R Habenicht; Holger M Reichardt; François Tronche; Wolfgang Schmid; Günther Schütz
Journal:  J Clin Invest       Date:  2007-04-19       Impact factor: 14.808

5.  Expression profiles of human 11beta-hydroxysteroid dehydrogenases type 1 and type 2 in inflammatory bowel diseases.

Authors:  J P Stegk; B Ebert; H-J Martin; E Maser
Journal:  Mol Cell Endocrinol       Date:  2008-10-31       Impact factor: 4.102

6.  Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis.

Authors:  J Keffer; L Probert; H Cazlaris; S Georgopoulos; E Kaslaris; D Kioussis; G Kollias
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

7.  Glucocorticoid repression of inflammatory gene expression shows differential responsiveness by transactivation- and transrepression-dependent mechanisms.

Authors:  Elizabeth M King; Joanna E Chivers; Christopher F Rider; Anne Minnich; Mark A Giembycz; Robert Newton
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

8.  Characterisation of fibroblast-like synoviocytes from a murine model of joint inflammation.

Authors:  Rowan S Hardy; Claudia Hülso; Yingling Liu; Sylvia J Gasparini; Colette Fong-Yee; Jinwen Tu; Shihani Stoner; Paul M Stewart; Karim Raza; Mark S Cooper; Markus J Seibel; Hong Zhou
Journal:  Arthritis Res Ther       Date:  2013-01-29       Impact factor: 5.156

9.  A SULT2A1 genetic variant identified by GWAS as associated with low serum DHEAS does not impact on the actual DHEA/DHEAS ratio.

Authors:  Robin Haring; Henri Wallaschofski; Alexander Teumer; Heyo Kroemer; Angela E Taylor; Cedric H L Shackleton; Matthias Nauck; Uwe Völker; Georg Homuth; Wiebke Arlt
Journal:  J Mol Endocrinol       Date:  2012-12-31       Impact factor: 5.098

10.  Therapeutic glucocorticoids prevent bone loss but drive muscle wasting when administered in chronic polyarthritis.

Authors:  C G Fenton; J M Webster; C S Martin; S Fareed; C Wehmeyer; H Mackie; R Jones; A P Seabright; J W Lewis; Y C Lai; C S Goodyear; S W Jones; M S Cooper; G G Lavery; R Langen; K Raza; R S Hardy
Journal:  Arthritis Res Ther       Date:  2019-08-01       Impact factor: 5.156

View more
  6 in total

1.  11β-Hydroxysteroid Dehydrogenase Type 1 within Osteoclasts Mediates the Bone Protective Properties of Therapeutic Corticosteroids in Chronic Inflammation.

Authors:  Chloe G Fenton; Ana Crastin; Claire S Martin; Saicharan Suresh; Isabella Montagna; Bismah Hussain; Amy J Naylor; Simon W Jones; Morten S Hansen; Caroline M Gorvin; Maria Price; Andrew Filer; Mark S Cooper; Gareth G Lavery; Karim Raza; Rowan S Hardy
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

Review 2.  Distinct Glucocorticoid Receptor Actions in Bone Homeostasis and Bone Diseases.

Authors:  Sooyeon Lee; Benjamin Thilo Krüger; Anita Ignatius; Jan Tuckermann
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-10       Impact factor: 5.555

Review 3.  Endogenous Glucocorticoid Metabolism in Bone: Friend or Foe.

Authors:  Claire S Martin; Mark S Cooper; Rowan S Hardy
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-27       Impact factor: 5.555

Review 4.  The Role of Glucocorticoids in Inflammatory Diseases.

Authors:  Sybille D Reichardt; Agathe Amouret; Chiara Muzzi; Sabine Vettorazzi; Jan P Tuckermann; Fred Lühder; Holger M Reichardt
Journal:  Cells       Date:  2021-10-28       Impact factor: 6.600

5.  Effects of HSD11B1 knockout and overexpression on local cortisol production and differentiation of mesenchymal stem cells.

Authors:  Angelique Kragl; Janosch Schoon; Ana Tzvetkova; Christoph Wenzel; Martina Blaschke; Wolfgang Böcker; Heide Siggelkow; Mladen V Tzvetkov
Journal:  Front Bioeng Biotechnol       Date:  2022-08-25

6.  Global Deletion of 11β-HSD1 Prevents Muscle Wasting Associated with Glucocorticoid Therapy in Polyarthritis.

Authors:  Justine M Webster; Michael S Sagmeister; Chloe G Fenton; Alex P Seabright; Yu-Chiang Lai; Simon W Jones; Andrew Filer; Mark S Cooper; Gareth G Lavery; Karim Raza; Ramon Langen; Rowan S Hardy
Journal:  Int J Mol Sci       Date:  2021-07-22       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.